Year: 2018
Type: article
Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cells (CART19) immunotherapy has proved to be extremely successful in B cell leukemia and lymphoma,1 and based on the beneficial results of several clinical trials, two CART19 products are now commercially available in the US.2,3 However, together with the striking antitumor effects, significant toxicities are associated with CAR T treatment—in particular, cytokine release syndrome (CRS) and neurotoxicity. CAR T toxicities are quite unique and specific to this potent treatment.
Source: Molecular Therapy
Authors: Marco Ruella, Carl H. June
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2803886735